Decoding Risks and Rewards in Ischemic Stroke Surgery
- Conditions
- Ischemic Stroke
- Registration Number
- NCT06098066
- Lead Sponsor
- China Medical University Hospital
- Brief Summary
In the high-stakes battle against ischemic cerebrovascular disease, where every second counts and the margin for error is slim, how do the investigators tip the scales in favor of patient survival and improved outcomes? This groundbreaking study, the first nationwide, population-based analysis with long-term follow-up in an Asian context, dives deep into this critical question. Leveraging an expansive dataset from Taiwan's National Health Insurance Research Database, the investigators scrutinize the efficacy and risks of aggressive surgical interventions-specifically, EC-IC bypass, CEA, and CAS-in a cohort of over 84,000 patients.
This paper serves as a milestone, bridging the gap between medical idealism and clinical reality. It calls for a surgical renaissance, emphasizing the need for refining techniques and enhancing patient selection protocols. If participants're looking for a comprehensive, nuanced, and, above all, actionable insight into the surgical treatment of ischemic cerebrovascular disease, this is the study that could redefine the paradigm.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 204411
- All participants underwent either a computed tomography (CT) scan or magnetic resonance imaging (MRI) within two days before or after hospital admission.
The date of the first ischemic stroke hospitalization served as the index event.
Among these patients, those who underwent surgical interventions post-hospitalization were categorized into three distinct groups: CEA (ICD-9-CM code 3812), CAS (ICD-9-CM code 3990), and EC-IC (ICD-9-CM code 3928), with the operation date being the index date.
Those who did not receive any surgical interventions were considered the non-intervention control group and had their first hospitalization date as the index date.
- patients with a history of: any stroke subtype (ICD-9-CM codes 430-434), Moyamoya disease (ICD-9-CM code 437.5), cancer (ICD-9-CM codes 140-239), trauma (various ICD-9-CM codes), transient ischemic attack (ICD-9-CM code 435), unruptured cerebral aneurysm (ICD-9-CM code 437.3), or subarachnoid hemorrhage (ICD-9-CM code 430).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rehospitalization Follow-up assessments were planned at 3 months, 6 months, 1 year, 2 years, and 3 years post-index date rehospitalization due to ischemic or hemorrhagic stroke
- Secondary Outcome Measures
Name Time Method Cardiac events Follow-up assessments were planned at 3 months, 6 months, 1 year, 2 years, and 3 years post-index date congestive heart failure and acute myocardial infarction were also monitored throughout the study period.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
China Medical University Hospital
🇨🇳Taichung, Taiwan
China Medical University Hospital🇨🇳Taichung, Taiwan